INNO-406

Known as: Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[(3S)-3- (dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-, CNS-9 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2015
0520052015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
OBJECTIVE Advanced systemic mastocytosis (SM) is characterized by uncontrolled growth of neoplastic mast cells (MC) and drug… (More)
Is this relevant?
2009
2009
IL-10 is a multifunctional cytokine that plays a critical role in maintaining the balance between immunity and tolerance… (More)
Is this relevant?
2008
2008
We compared the growth-inhibitory effects and inhibition profile of the SRC family kinases (SFKs) of imatinib, dasatinib… (More)
Is this relevant?
2008
2008
Bcr-Abl tyrosine kinase (TK) inhibitors are promising therapeutic agents for Bcr-Abl-positive (Bcr-Abl+) leukemias. Although they… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2008
2008
Because imatinib (IM) resistance in chronic myeloid leukemia is primarily caused by the re-establishment of Abl kinase, new… (More)
  • table I
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
Bcr-Abl is the cause of Philadelphia-positive (Ph+) leukemias and also constitutes their principal therapeutic target, as… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
Central nervous system (CNS) relapse accompanying the prolonged administration of imatinib mesylate has recently become apparent… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
The activity of the novel tyrosine kinase inhibitor INNO-406 against human cells with mutated KIT was investigated. Human mast… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Although the Abelson (Abl) tyrosine kinase inhibitor imatinib mesylate has improved the treatment of breakpoint cluster region… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?